FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011344992> ?p ?o ?g. }

• W2011344992 endingPage "953" @default.
• W2011344992 startingPage "936" @default.
• W2011344992 abstract "Community-acquired pneumonia remains an important infectious disease problem, with more than 4 million cases occurring in the United States annually. Although Streptococcus pneumoniae remains the most commonly identified organism, a variety of bacterial and nonbacterial pathogens may be involved. Hospitalization is unnecessary in most cases, and oral antibiotic therapy is common. In the majority of cases, the etiology of pneumonia is unknown at the time of presentation, necessitating the use of empiric therapy. Quinolones have not been utilized in this setting in the past because of their inconsistent coverage of S pneumoniae. Sparfloxacin (RP 64206) is a broad-spectrum fluoroquinolone with excellent activity in vitro against the majority of bacteria involved in community-acquired pneumonia, including pneumococcus. We therefore studied the efficacy and safety of sparfloxacin compared with the second-generation cephalosporin cefaclor as empiric therapy for patients with community-acquired pneumonia in a double-masked, double-dummy, multicenter trial. Three hundred thirty patients aged 18 years or older with community-acquired pneumonia suspected of being bacterial in etiology were enrolled at 74 centers in the United States from June 1, 1992, to March 4, 1995. Patients meeting the inclusion criteria were randomized to receive 10 days of either sparfloxacin 400 mg orally once followed by sparfloxacin 200 mg orally daily (n = 168), or cefaclor 500 mg orally every 8 hours (n = 162). There were no significant differences between groups with regard to baseline characteristics. Patients were followed up serially at 4 ± 1 days, 20 ± 3 days, and 38 ± 7 days after the beginning of therapy. Patients were evaluated for clinical response, clinical recurrence of infection, and eradication of baseline pathogens. The primary efficacy variable was the clinical response (cured or improved) in the subgroup of patients meeting the definition of clinically assessable. Responses were also evaluated in the intent-to-treat population. In the intent-to-treat population, 35.7% of patients receiving sparfloxacin were clinically cured, compared with 32.1% of patients receiving cefaclor. Clinical successes (patients clinically cured plus improved) were also comparable (72.6% of patients in the sparfloxacin group and 71.0% of patients in the cefaclor group). Similar clinical success rates were noted using only the clinically assessable population (primary efficacy variable). Forty-four percent of patients receiving sparfloxacin and 39.1% of patients receiving cefaclor were clinically cured. In the sparfloxacin group, 86.6% of patients were clinical successes, compared with 84.4% of patients in the cefaclor group. Microbiologic cures were comparable in both groups. There was no difference in the incidence of recurrence of infection or superinfection. Adverse events thought to be due to study drug occurred equally in both groups (14.3% in the sparfloxacin group vs 14.8% in the cefaclor group). Results show that sparfloxacin is a safe and effective empiric therapy for patients with community-acquired pneumonia and is comparable to cefaclor." @default.
• W2011344992 created "2016-06-24" @default.
• W2011344992 creator A5000703157 @default.
• W2011344992 creator A5027292997 @default.
• W2011344992 creator A5030455530 @default.
• W2011344992 creator A5056016798 @default.
• W2011344992 creator A5057304477 @default.
• W2011344992 creator A5080609948 @default.
• W2011344992 creator A5083309208 @default.
• W2011344992 date "1997-09-01" @default.
• W2011344992 modified "2023-10-16" @default.
• W2011344992 title "Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study" @default.
• W2011344992 cites W1554503945 @default.
• W2011344992 cites W1974746996 @default.
• W2011344992 cites W1978475645 @default.
• W2011344992 cites W2000222593 @default.
• W2011344992 cites W2003312939 @default.
• W2011344992 cites W2003734656 @default.
• W2011344992 cites W2020418992 @default.
• W2011344992 cites W2027162482 @default.
• W2011344992 cites W2027461673 @default.
• W2011344992 cites W2031746612 @default.
• W2011344992 cites W2035770570 @default.
• W2011344992 cites W2037437120 @default.
• W2011344992 cites W2040919444 @default.
• W2011344992 cites W2049122089 @default.
• W2011344992 cites W2051279180 @default.
• W2011344992 cites W2069823148 @default.
• W2011344992 cites W2072298306 @default.
• W2011344992 cites W2073551102 @default.
• W2011344992 cites W2077667189 @default.
• W2011344992 cites W2083733667 @default.
• W2011344992 cites W2087682120 @default.
• W2011344992 cites W2091953741 @default.
• W2011344992 cites W2122590159 @default.
• W2011344992 cites W2153296766 @default.
• W2011344992 cites W2156770733 @default.
• W2011344992 cites W2157973654 @default.
• W2011344992 cites W2423036980 @default.
• W2011344992 cites W3145041166 @default.
• W2011344992 cites W3146425871 @default.
• W2011344992 cites W3200858890 @default.
• W2011344992 cites W2017855650 @default.
• W2011344992 doi "https://doi.org/10.1016/s0149-2918(97)80047-1" @default.
• W2011344992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9385482" @default.
• W2011344992 hasPublicationYear "1997" @default.
• W2011344992 type Work @default.
• W2011344992 sameAs 2011344992 @default.
• W2011344992 citedByCount "38" @default.
• W2011344992 countsByYear W20113449922012 @default.
• W2011344992 countsByYear W20113449922014 @default.
• W2011344992 countsByYear W20113449922018 @default.
• W2011344992 crossrefType "journal-article" @default.
• W2011344992 hasAuthorship W2011344992A5000703157 @default.
• W2011344992 hasAuthorship W2011344992A5027292997 @default.
• W2011344992 hasAuthorship W2011344992A5030455530 @default.
• W2011344992 hasAuthorship W2011344992A5056016798 @default.
• W2011344992 hasAuthorship W2011344992A5057304477 @default.
• W2011344992 hasAuthorship W2011344992A5080609948 @default.
• W2011344992 hasAuthorship W2011344992A5083309208 @default.
• W2011344992 hasConcept C126322002 @default.
• W2011344992 hasConcept C137627325 @default.
• W2011344992 hasConcept C141071460 @default.
• W2011344992 hasConcept C142724271 @default.
• W2011344992 hasConcept C168563851 @default.
• W2011344992 hasConcept C177713679 @default.
• W2011344992 hasConcept C204787440 @default.
• W2011344992 hasConcept C2776102371 @default.
• W2011344992 hasConcept C2776345407 @default.
• W2011344992 hasConcept C2777914695 @default.
• W2011344992 hasConcept C2778049240 @default.
• W2011344992 hasConcept C2778512257 @default.
• W2011344992 hasConcept C2779181126 @default.
• W2011344992 hasConcept C2779766023 @default.
• W2011344992 hasConcept C2780926990 @default.
• W2011344992 hasConcept C2781253189 @default.
• W2011344992 hasConcept C501593827 @default.
• W2011344992 hasConcept C64778159 @default.
• W2011344992 hasConcept C71924100 @default.
• W2011344992 hasConcept C86803240 @default.
• W2011344992 hasConcept C89423630 @default.
• W2011344992 hasConceptScore W2011344992C126322002 @default.
• W2011344992 hasConceptScore W2011344992C137627325 @default.
• W2011344992 hasConceptScore W2011344992C141071460 @default.
• W2011344992 hasConceptScore W2011344992C142724271 @default.
• W2011344992 hasConceptScore W2011344992C168563851 @default.
• W2011344992 hasConceptScore W2011344992C177713679 @default.
• W2011344992 hasConceptScore W2011344992C204787440 @default.
• W2011344992 hasConceptScore W2011344992C2776102371 @default.
• W2011344992 hasConceptScore W2011344992C2776345407 @default.
• W2011344992 hasConceptScore W2011344992C2777914695 @default.
• W2011344992 hasConceptScore W2011344992C2778049240 @default.
• W2011344992 hasConceptScore W2011344992C2778512257 @default.
• W2011344992 hasConceptScore W2011344992C2779181126 @default.
• W2011344992 hasConceptScore W2011344992C2779766023 @default.
• W2011344992 hasConceptScore W2011344992C2780926990 @default.
• W2011344992 hasConceptScore W2011344992C2781253189 @default.
• W2011344992 hasConceptScore W2011344992C501593827 @default.

• next